XTX Topco Ltd Acquires Shares of 27,660 Climb Bio, Inc. (NASDAQ:CLYM)

XTX Topco Ltd acquired a new stake in shares of Climb Bio, Inc. (NASDAQ:CLYM) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 27,660 shares of the company’s stock, valued at approximately $34,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bank of New York Mellon Corp bought a new stake in Climb Bio during the 1st quarter valued at about $79,000. TD Asset Management Inc bought a new stake in Climb Bio during the 1st quarter valued at about $109,000. Finally, Peapod Lane Capital LLC bought a new stake in Climb Bio during the 1st quarter valued at about $676,000. 69.76% of the stock is currently owned by institutional investors.

Climb Bio Stock Up 10.5%

Shares of CLYM stock opened at $1.90 on Friday. The company has a 50 day moving average price of $1.41 and a 200-day moving average price of $1.37. Climb Bio, Inc. has a 52 week low of $1.05 and a 52 week high of $8.79. The firm has a market capitalization of $128.75 million, a PE ratio of -2.71 and a beta of -0.11.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06. Analysts anticipate that Climb Bio, Inc. will post -1.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CLYM. Baird R W upgraded shares of Climb Bio to a “strong-buy” rating in a research note on Friday. BTIG Research assumed coverage on shares of Climb Bio in a research note on Thursday, May 22nd. They issued a “buy” rating for the company. Robert W. Baird assumed coverage on shares of Climb Bio in a research note on Friday. They issued an “outperform” rating and a $9.00 price target for the company. Finally, Oppenheimer assumed coverage on shares of Climb Bio in a research note on Friday, June 6th. They issued an “outperform” rating and a $10.00 price target for the company. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $9.00.

Climb Bio Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.